The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 

The positive opinion was issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The opinion is based on data from the Phase III inMIND trial evaluating the efficacy and safety of Minjuvi in combination with rituximab and lenalidomide in 548 adult patients with relapsed or refractory FL. When combined with rituximab and lenalidomide, Minjuvi met its primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival (PFS). 

FL is the most common slow-growing form of B-cell non-Hodgkin lymphoma (NHL), representing about 30% of NHL cases globally. It is considered incurable, with patients frequently relapsing after initial therapy and experiencing a progressively worsening prognosis with each recurrence.  

Despite advances in treatment, there remains a significant unmet need for additional options for relapsed or refractory FL, with two to four out of every 100,000 people affected in Western countries. 

 “If approved, Minjuvi in combination with rituximab and lenalidomide will represent the first CD19- and CD20- dual-targeted immunotherapy for patients in Europe living with relapsed or refractory FL,” said Lee Heeson, Executive Vice President and Head of Incyte International, the global biopharmaceutical company that developed Minjuvi. 

“Based on the inMIND clinical trial results, Minjuvi has demonstrated its ability to offer patients improved progression-free survival. The positive CHMP opinion is an encouraging step in our ongoing efforts to advance treatments that address critical gaps for patients.” 

The CHMP opinion is now being reviewed by the European Commission, which has the authority to grant approval for all centrally authorised products in the EU. If approved, this would mark the second indication for Minjuvi, which was previously approved by the European Commission in combination with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 

 

Bruno Quinney, Content Team, DDW